Document Detail


The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies.
MedLine Citation:
PMID:  20860414     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypertension remains a significant health problem, affecting approximately 30% of the US population. Of these, only 36.8% have BP controlled to recommended levels of <140/90 mmHg for uncomplicated hypertension and <130/80 mmHg for patients with diabetes mellitus or renal disease. For those with uncontrolled hypertension, the risk of diabetes, renal disease, stroke, and cardiovascular disease is increased. Therapeutic options for the treatment of hypertension include several major classes of drugs: diuretics, β-adrenoceptor antagonists (β-blockers), ACE inhibitors, angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), renin inhibitors, calcium channel blockers, and central sympatholytics, alone or in combination. Guidelines recommend thiazide diuretics as preferred first-line monotherapy. However, only 50% of patients will respond adequately to this therapy and the rest will require two or more antihypertensive agents to achieve BP goals. Clinical evidence demonstrates that some drugs have advantages when used in combination rather than as monotherapy. Drugs that block the renin-angiotensin-aldosterone system not only provide BP control but may also provide vascular protection and are metabolically neutral. This is a concise review of the safety and efficacy of ARBs in combination with amlodipine for the treatment of hypertension, with focus on the telmisartan-amlodipine combination. A MEDLINE search of the English literature from 2006 to 2009 of amlodipine in combination with ARBs revealed six publications, which are included in this review.
Authors:
Steven G Chrysant
Related Documents :
8539204 - Hypertensive crises. the need for urgent management.
15365284 - Diuretic-related side effects: development and treatment.
20813434 - Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: synthesis and...
19918164 - Statins in hypertension: are they a new class of antihypertensive agents?
19935304 - Tibial nerve decompression in patients with tarsal tunnel syndrome: pressures in the ta...
11386794 - Haemodynamics of arteriovenous malformations of the brain and consequences of resection...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  10     ISSN:  1175-3277     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-23     Completed Date:  2011-01-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  315-20     Citation Subset:  IM    
Affiliation:
Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, Oklahoma, USA. schrysant@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin Receptor Antagonists / administration & dosage*
Calcium Channel Blockers / administration & dosage*
Drug Therapy, Combination
Humans
Hypertension / drug therapy*
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Calcium Channel Blockers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hyperchol...
Next Document:  Cardiovascular risk-benefit profile of sibutramine.